Investment Thesis
Medtronic demonstrates strong free cash flow generation ($5.4B) and adequate balance sheet leverage, but concerning fundamentals including a 10.3% gross margin (anomalously low for medical devices), declining net income despite massive revenue growth, and weak return metrics (ROE 9.7%, ROA 5.2%) suggest significant operational challenges or integration issues requiring clarification.
Strengths
- Robust free cash flow generation of $5.4B with 14.9% FCF margin demonstrates underlying business cash generation
- Strong liquidity position with 2.13x current ratio and 1.62x quick ratio, supporting operational flexibility
- Manageable leverage of 0.57x debt/equity with 9.0x interest coverage indicates capacity to service debt obligations
Risks
- Extremely low gross margin of 10.3% is structurally problematic for medical device sector and suggests cost pressures or unfavorable business mix
- Net income declined 0.7% YoY despite 9,394.5% revenue growth, indicating severe operational deleverage or integration drag
- Weak capital efficiency with ROE 9.7% and ROA 5.2% suggests inefficient asset deployment or earning power challenges
Key Metrics to Watch
- Gross margin trend - determine if 10.3% is structural deterioration or temporary integration cost
- Operating leverage improvement - net income must grow faster than revenue as integration completes
- Cash position - $1.9B cash against $28.1B debt is low; monitor cash generation allocation to debt reduction
Financial Metrics
Revenue
36.4B
Net Income
4.8B
EPS (Diluted)
$3.73
Free Cash Flow
5.4B
Total Assets
93.0B
Cash
1.9B
Profitability Ratios
Gross Margin
10.3%
Operating Margin
17.8%
Net Margin
13.2%
ROE
9.7%
ROA
5.2%
FCF Margin
14.9%
Balance Sheet & Liquidity
Current Ratio
2.13x
Quick Ratio
1.62x
Debt/Equity
0.57x
Debt/Assets
46.2%
Interest Coverage
8.99x
Long-term Debt
28.1B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-06-19T07:15:28.751240 |
Data as of: 2026-04-24 |
Powered by Claude AI